Cargando…

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

BACKGROUND: HBV and HCV reactivation have been widely reported in patients undergoing immunosuppressive therapy (IT); however, few data are available on the risk of reactivation in patients with psoriasis receiving IT. The aim of our study was to assess the prevalence of HBV and HCV infection in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morisco, Filomena, Guarino, Maria, La Bella, Serena, Di Costanzo, Luisa, Caporaso, Nicola, Ayala, Fabio, Balato, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279461/ https://www.ncbi.nlm.nih.gov/pubmed/25523080 http://dx.doi.org/10.1186/s12876-014-0214-x

Ejemplares similares

HBsAb and HBcAb Have No Significant Effect on the Progression of SLE and RA
por: WANG, Fen, et al.
Publicado: (2017)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

Prevalence of Cirrhosis/Advanced Fibrosis Among HBsAg-Negative and HBcAb-Positive US Adults: A Nationwide Population-Based Study
por: Huang, Shuai-Wen, et al.
Publicado: (2022)

Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy
por: Lin, Ying-Cheng, et al.
Publicado: (2021)

Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis
por: Hong, Xuezhi, et al.
Publicado: (2023)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study
por: Tien, Ya-Chih, et al.
Publicado: (2018)

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
por: Masarone, Mario, et al.
Publicado: (2014)

HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma
por: Wang, Wen‐Qiang, et al.
Publicado: (2023)

Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
por: Giordano, Claudia, et al.
Publicado: (2023)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review
por: Cholongitas, Evangelos, et al.
Publicado: (2018)

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
por: Bedi, Harjot K., et al.
Publicado: (2021)

Effectiveness of blood donor screening by HIV, HCV, HBV‐NAT assays, as well as HBsAg and anti‐HBc immunoassays in Germany (2008–2015)
por: Fiedler, Sarah A., et al.
Publicado: (2019)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2016)

HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy
por: Malagnino, Vincenzo, et al.
Publicado: (2019)

Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B
por: Madhavan, Anitha, et al.
Publicado: (2021)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
por: Wang, Wen-Xin, et al.
Publicado: (2022)

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
por: Zhang, Xi, et al.
Publicado: (2021)

Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine
por: Gholizadeh, Monireh, et al.
Publicado: (2015)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
por: Guarino, Maria, et al.
Publicado: (2020)

Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients
por: Mohammadi, Mohsen, et al.
Publicado: (2009)

Using dried blood spot for the detection of HBsAg and anti-HCV antibodies in Cameroon
por: Kenmoe, Sebastien, et al.
Publicado: (2018)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
por: Imperatore, Nicola, et al.
Publicado: (2017)

In vitro expression of precore proteins of hepatitis B virus subgenotype A1 is affected by HBcAg, and can affect HBsAg secretion
por: Deroubaix, Aurélie, et al.
Publicado: (2021)

Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
por: Kan, Karin, et al.
Publicado: (2023)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ta3hsgh71jh2i8ocf647efv3vi